STANDARD BIOTOOLS INC. files 10-Q

Standard BioTools Inc. reported a net income of $127.1 million for the quarter ended March 31, 2026, a significant increase from a net loss of $26.0 million in the prior year period, largely due to the gain from the sale of its SomaScan Business. The company's continuing operations, however, reported a net loss of $14.6 million.